Advances in Cancer Research
Regular price
64.750 KD
inc. VAT
Couldn't load pickup availability
Table of contents
- Contentsv
- Contributors to Volume 85ix
- Chapter 1. The Von Hippel–Lindau Tumor Suppressor Complex and Regulation of Hypoxia-Inducible Tran1
- I. The VHL Protein Regulates Transcription of Hypoxia-Inducible Genes2
- II. The VHL Tumor Suppressor Protein is A Subunit of an E3 Ubiquitin Ligase that Targets HIFa Subu3
- III. Prolyl Hydroxylase: The Oxygen Sensor in Hypoxic Signaling?6
- IV. Conclusion7
- References8
- Chapter 2. Retinoblastoma Tumor Suppressor and Genome Stability13
- I. Introduction14
- II. Rb and Chromosome Segregation16
- III. Rb and Chromosome Replication26
- IV. Rb and DNA Damage Response28
- V. Global Connections of Rb and Chromatin31
- VI. Haploinsufficiency of Rb in Maintaining Genome Stability36
- VII. Perspectives38
- References40
- Chapter 3. The Abl Family Kinases: Mechanisms of Regulation and Signaling51
- I. Introduction51
- II. The Abl Tyrosine Kinases: Structure and Conservation52
- III. Expression Patterns and Subcellular Localization57
- IV. Regulation of Abl Tyrosine Kinase Activity59
- V. Role of Abl Kinases in The Regulation of Cell Growth and Survival74
- VI. Role of Abl Kinases in Cellular Stress Responses77
- VII. Role of Abl Kinases in The Regulation of Cytoskeletal Dynamics80
- VIII. What are the Substrates of Abl Kinases in Normal Cells?88
- IX. Conclusions and Future Directions89
- References91
- Chapter 4. Cellular Immunity to the Her-2/neu Protooncogene101
- I. Introduction102
- II. The HER Receptor Family and its Ligands103
- III. HER-2 and Cellular Transformation105
- IV. HER-2 Overexpression in Tumors of Different Histology106
- V. Validity of Methods Employed for the Assessment of HER-2/neu Status108
- VI. HER-2 as a Shared Tumor-Associated Antigen109
- VII. New Treatment Modalities for HER-2-Overexpressing Tumor Cells114
- VIII. HER-2/neu Expression and Immune Escape121
- IX. Clinical Trials Based on HER-2-Specific Tumor Vaccines126
- X. Concluding Remarks and Future Directions131
- References133
- Chapter 5. A New Challenge for Successful Immunotherapy by Tumors That Are Resistant to Apoptosis: T145
- I. Introduction146
- II. Apoptosis as Cytotoxic Mechanisms of T Lymphocytes149
- III. The Road Map of Apoptosis: All Roads Lead to Caspases150
- IV. Cross-Talking between the Two Apoptotic Pathways and Cross-Resistance153
- V. Inhibition of Apoptosis as a Mechanism of Cross-Resistance154
- VI. Sensitization of Resistant Tumor Cells to Cytotoxic Lymphocytes/Factors-Mediated Apoptosis156
- VII. Conclusions164
- References167
- Chapter 6. Cell Volume and Ion Changes during Apoptotic Cell Death175
- I. The Universality of Apoptotic Volume Decrease176
- II. The Cell Volume ''constancy''177
- III. The Role of Cell Death-Induced Ion Movements across the Plasma Membrane179
- IV. Signal Transduction Mechanisms and Apoptotic Volume Decrease191
- V. Concluding Remarks194
- References194
- Chapter 7. Mitochondria and Apoptosis: New Therapeutic Targets203
- I. Introduction203
- II. Review of Metabolic Changes in Cancer Cells204
- III. Targeting Abnormal Metabolism in Cancer Cells206
- IV. Selective Distribution of Compounds in Cancer Mitochondria207
- V. Mitochondrial Pathways in Apoptosis209
- VI. Permeability Transition Pores in Apoptosis210
- VII. Apoptotic Regulators in Mitochondria220
- Viii. Conclusions230
- References230
- Index243
Advances in Cancer Research